Author: Catalytic Agency

Posted Date:

May 12, 2026

New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats

Catalytic Agency

May 12, 2026
Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans

Catalytic Agency

May 4, 2026
Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

Catalytic Agency

April 28, 2026